Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AN4005
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Adlai Nortye
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : This includes the rights and interests of Adlai Nortye in the development, manufacturing and commercialization of AN4005 and AN3025 in Greater China, and AN1005, AN6015 and AN9015 worldwide.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 26, 2022
Lead Product(s) : AN4005
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Adlai Nortye
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Reset All
